Kathryn J Swoboda
Massachusetts General Hospital · University of Utah · University of Utah/Primary Children's Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kathryn J Swoboda as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:36 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02831296 · Prospective Evaluation of Infants With Spinal Muscular Atrophy:Massachusetts General Hospital · unknown · Spinal Muscular Atrophy · principal investigator
- Ph1/Ph2NCT01425528 · Study of Kuvan Treatment in Adults With GTPCH DeficiencyUniversity of Utah · completed · GTP Cyclohydrolase Deficiency · principal investigator
- Ph1/Ph2NCT00931164 · Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)University of Utah · completed · Alternating Hemiplegia of Childhood · principal investigator
- Ph2NCT00481013 · Valproic Acid in Ambulant Adults With Spinal Muscular AtrophyUniversity of Utah · completed · Spinal Muscular Atrophy · principal investigator
- Ph1NCT00374075 · Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular AtrophyUniversity of Utah · completed · Spinal Muscular Atrophy · principal investigator
- Ph2NCT00227266 · Valproic Acid and Carnitine in Patients With Spinal Muscular AtrophyUniversity of Utah · completed · Spinal Muscular Atrophy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Neural and non-neural contributions to phenotype in human SMA type 1R21NS108015 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2018 to 2019 · $252,750 awarded in 2019Same name and institution; not confirmed by an ID
- Newborn screening for identification & prospective followup of infants with SMAR01HD069045 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2011 to 2015 · $862,570 awarded in 2015Grant number is on one of their registry trials
- The Utah Regional Network for Excellence in Neuroscience Clinical TrialsU10NS077305 · NINDS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2011 to 2013 · $298,000 awarded in 2013Same name and institution; not confirmed by an ID
- Therapeutic Opportunities in Spinal Muscular AtrophyR01HD054599 · NICHD · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2007 to 2011 · $256,506 awarded in 2011Same name and institution; not confirmed by an ID
- CLINICAL TRIAL: VALPROIC ACID AND CARNITINE IN PATIENTS WITH SPINAL MUSCULAR ATRM01RR000064 · NCRR · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2004 to 2008 · $46,821 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:36 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.Neuromuscul Disord · 2019509 citationsRCR 23.3
- Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.Neurology · 2016502 citationsRCR 17.0
- Natural history of denervation in SMA: relation to age, SMN2 copy number, and function.Ann Neurol · 2005387 citationsRCR 9.1
- 276 citationsRCR 22.7
- 242 citationsRCR 19.8
- Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.Neurology · 2019213 citationsRCR 9.7
- Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.J Child Neurol · 2016178 citationsRCR 6.2
- Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment.J Clin Invest · 2019158 citationsRCR 6.6
- 133 citationsRCR 3.3
- Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study.PLoS One · 2012132 citationsRCR 3.9